Author weighs SLS as a potential biotech breakout if Phase 3 cancer results are positive, while cautioning about headline-driven crash risk.
SLS — WATCH The author notes SLS's product is reported to treat roughly 20 types of cancer and that positive Phase 3 results could cause the valuation to explode. The causal mechanism is successful Phase 3 data validating the product's broad cancer potential, which would drive a sharp re-rating. The main stated risk is that headline-driven biotech stocks such as ATRA, C3.ai, and SAVA have often been crushed after similar runs.
I think if their Phase 3 results come back positive, the valuation could absolutely explode.
This Reddit post, published January 02, 2026, features u/Fortune756 discussing SLS. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/Fortune756 · Tickers: SLS